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POSTER ABSTRACTS
Odd-numbered posters will be presented in Poster Session 01 on 
Tuesday, 23 October from 17:30 – 19:30 in the Poster Hall. 
 
Even-numbered posters will be presented in Poster Session 02 on 
Wednesday, 24 October from 17:30 – 19:30 in the Poster Hall.
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P09.06
Mechanical Testing Protocols for Vaginal Ring 
Formulations
Clare F. McCoy 1, Peter Boyd 1, Diarmaid J. Murphy 1, R. Karl Malcolm 1, 
Wendy Blanda 2, Patrick Spence 2, Brid Devlin 2
1Queen‘s University Belfast, United Kingdom, 2International 
Partnership for Microbicides, United States
Background: There are currently no international standards regarding 
mechanical testing and properties of vaginal rings. Here, we report 
the development of a series of mechanical protocols aligned to ISO 
8009:2014 (“Mechanical contraceptive - reusable natural and silicone 
rubber contraceptive diaphragms - requirement and tests”) to aid 
evaluation and comparison of IPM‘s 25 mg dapivirine (DPV) matrix 
ring against a range of marketed vaginal ring (VR) products.
Methods: Based on the methodology described in ISO8009, various 
custom mechanical tests and test apparatus were designed and 
developed by Queen‘s University Belfast. Three marketed VR 
products (NuvaRing®, Femring® and Estring®) were evaluated 
alongside three batches of IPM‘s 25 mg DPV ring, one batch of 200 
mg DPV rings and one batch of 200-320 mg DPV+levonorgestrel 
(LNG) rings. All rings were evaluated for weight, cross-sectional 
diameter, outer diameter (OD), hardness (Shore A and Shore M), 
mean tensile extension, 28-day static compression, 1000-cycle 
compression and twist during compression testing.
Results: IPM‘s 25 mg and 200 mg DPV rings recovered 90-100% 
of their original OD following 28-day static compression. Femring® 
was the only product to recover 100% of its original OD. During 
tensile testing, the 25 mg DPV ring batches endured mean tensile 
loads of 68-69 kg before fracture compared to 14 kg, 28 kg, and 71 
kg for Nuvaring®, Femring® and Estring®, respectively. On completion 
of 1000-cycle compression testing, the 25 mg DPV rings, 200 mg 
DPV rings, 200-320 DPV-LNG rings and Femring® showed no 
visible deterioration and returned to 100% of their original OD. 
By comparison, the Nuvaring® devices were visibly deformed and 
recovered only 80% of their original OD.
Conclusions: ISO8009 was used as a framework to develop a 
series of mechanical tests for ring devices. The results indicate that 
IPM‘s 25 mg DPV, 200 mg DPV and 200-320 mg DPV-LNG ring 
formulations exhibit similar mechanical properties and performance 
to the commercially available rings. 
P09.05
Impact of Intermittent Use on In Vitro Release and 
Residual Content of 25 mg Dapivirine Rings
Clare F. McCoy 1, Diarmaid J. Murphy 1, Peter Boyd 1, Tiffany Derrick 2, Pat 
Spence 2, Brid Devlin 2, R. Karl Malcolm 1
1Queen‘s University Belfast, United Kingdom, 2International 
Partnership for Microbicides, United States
Background: The current 25 mg dapivirine (DPV) matrix ring 
formulation is intended for continuous use over 28 days. However, 
poor user adherence remains a considerable challenge for the 
efficacy of microbicide-releasing vaginal products. Here, we report 
the impact of intermittent use on in vitro release and residual content 
of 25 mg DPV rings.
Methods: In vitro release testing of 25 mg DPV rings over 28-days 
was performed using different intermittent schedules, including: 
(i) continuous release, (ii) release on the first and last day, (iii) 
release for one day each week and (iv) release for the first and last 
week of the 28-day period. Release was performed using either 
isopropanol (IPA) and water (1:1 v/v) or simulated vaginal fluid (SVF) 
containing 0.2% w/v Tween 80. When periodically removed from the 
release medium, rings were stored at either ambient temperature 
or 4°C. Residual content analysis - using acetone extraction - was 
performed on rings after completion of in vitro release testing. DPV 
concentrations were quantified by HPLC.
Results: DPV release was significantly greater in IPA+water 
compared to SVF+Tween. The total amount of DPV released was 
proportional to the amount of time the rings spent in the release 
medium. No significant differences were observed in the release 
rates for rings stored at different temperatures. Residual content 
values were dependent on the total time of exposure to the release 
medium. Cumulative release values combined with residual content 
values gave mass balance values close to the mean content assay 
value provided for the ring batch.
Conclusions: In vitro release rates measured under intermittent in 
vitro release testing schedules were not significantly different from 
those observed under continuous release schedules, based on a 
direct comparison of release rates on equivalent days. Removal 
of rings from the release medium and subsequent storage did not 
substantially alter the in vitro release profiles when the rings were 
placed back into the release medium. Do
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